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Summary
The West of Scotland Coronary Prevention Study (WOSCOPS) 
showed that pravastatin reduced the risk of coronary heart disease
(CHD) events in 6,595 middle-aged hypercholesterolaemic men aged
45–64 years without prior myocardial infarction followed for an aver-
age of 4.9 years. We hypothesised prospectively (a) that baseline levels
of haemorheological variables were related to baseline and incident
CHD and to mortality; and (b) that reduction in lipoproteins by prava-
statin would lower plasma and blood viscosity, a potential contributory
mechanism to CHD events. We therefore studied plasma and blood 
viscosity, fibrinogen, haematocrit, and blood cell counts at baseline and
1 year. At baseline, plasma and blood viscosity were related to risk 
factors, CHD measures, and claudication. On univariate analysis, 
baseline levels of all rheological variables (except platelet count) were
related to incident CHD; CHD mortality; and total mortality. On multi-
variate analysis including baseline CHD and risk factors, plasma and
blood viscosity, haematocrit and white cell count each remained signi-
ficantly associated with incident CHD; while fibrinogen remained an
independent predictor of mortality (all p < 0.03). After one year, lipo-
protein reduction by pravastatin was associated with significant reduc-
tions (about one quarter of a standard deviation) in plasma viscosity
(mean difference 0.02 mPa.s, p <0.001) and in blood viscosity (mean
difference 0.06 mPa.s, p <0.001), but was not associated with sig-
nificant changes in other rheological variables. We therefore suggest
that pravastatin therapy, which reduces elevated lipoproteins in hyper-
cholesterolaemic men, may lower risks of CHD and mortality partly by
lowering plasma and blood viscosity. Further studies are required to
test this hypothesis.
Introduction
The West of Scotland Coronary Prevention Study (WOSCOPS) 
recently showed that treatment with pravastatin in moderately hyper-
cholesterolaemic men reduced the relative risk of coronary heart dis-
ease (CHD; first myocardial infarction or fatal CHD) by 31% (1). While
the proportional benefit was independent of other CHD risk factors, the
absolute benefit was greatest in subjects with the highest baseline risk
(2). These results are consistent with other trials of cholesterol and low
density lipoprotein (LDL) reduction, and with the relationships be-
tween cholesterol, LDL and CHD in epidemiological and observational
studies (3). The causal roles of cholesterol and LDL in CHD appear
partly due to their associations with coronary atherosclerosis, as shown
by necropsy and angiographic correlations and by angiographic studies
of cholesterol reduction (3). However, it seems unlikely that changes in
coronary atherosclerosis during cholesterol reduction are sufficient to
explain the early reduction in CHD events (3, 4).
Other mechanisms by which reductions in LDL and cholesterol
might reduce the risk of CHD events include reductions in activation
and rupture of arterial plaques and in superadded thrombosis; reduction
in endothelial dysfunction; and reduction in plasma and blood visco-
sity, the major rheological determinants of blood flow (3–6). LDL and
VLDL cholesterol are determinants of plasma and blood viscosity (5,
7–11) which in turn are related to risk of CHD in prospective epide-
miological studies (10, 12, 13, 14). The predictive value of plasma 
viscosity for CHD is partly related to the effects of fibrinogen as well as
lipoproteins (5, 10, 12, 13).
At the start of this study, we hypothesised (a) that baseline levels of
rheological variables were associated with baseline and incident CHD
and mortality (5), and (b) that pravastatin therapy, by reducing plasma
lipoproteins, would lower plasma and blood viscosity. We therefore
measured viscosity, fibrinogen, and blood cell counts at baseline and 
1 year; and now report their relationships to cardiovascular risk factors,
baseline and incident CHD, mortality, and pravastatin treatment.
Subjects and Methods
These have been described previously (1, 2, 15, 16). Briefly, the West of
Scotland Coronary Prevention Study randomised 6,595 men aged 45– 64 years
with LDL levels of 4.96 ± 0.44 mmol/L after dietary advice, to receive prava-
statin 40 mg each evening or placebo. The average follow-up period was 
4.9 years. Self-reported hypertension, diabetes, CHD, claudication, medication,
smoking habit, alcohol consumption and employment status were documented
and seated blood pressure measured. Baseline lipoprotein levels were determi-
Correspondence to: Prof. Gordon D. O. Lowe, University Department 
of Medicine, Royal Infirmary, 10 Alexandra Parade, Glasgow G31 2ER, UK –
Tel: + 44 141 211 5412; Fax: + 44 141 211 0414; E-mail: gdl1j@clinmed.gla.ac.
uk
* Members of the West of Scotland Coronary Prevention Study Group: 
J. Shepherd, S. Cobbe, I. Ford, C. Packard, P. Macfarlane, A. R. Lorimer, 
J. H. McKillop and C. G. Isles
554
Thromb Haemost 2000; 84: 553–8
ned from the mean of two fasting analyses performed at the second and third
screening visits at least 4 weeks apart following a minimum of 4 weeks dietary
advice.
At the third visit, a fasting venous blood sample was also anticoagulated
with K2 EDTA (1.5 mg/mL) for measurement of rheological variables. Plasma
viscosity was measured in a Coulter semi-automated capillary viscometer at
37° C (13). Plasma fibrinogen was assayed by heat precipitation nephelometry
(10, 12, 17, 18). Blood counts were performed on Coulter STKR or S +1 auto-
mated cell counters. High-shear whole-blood viscosity was calculated from
plasma viscosity and haematocrit according to the equation of Whittington and
Harkness (19) from data previously collected from West of Scotland men aged
45– 64 years in the Scottish Heart Health Study/Glasgow MONICA Study (8).
These measurements (except platelet count) were repeated at the 1 year study
visit. 
Statistical analyses were performed on all available data. Continuous varia-
bles were summarised by mean and SD. Spearman rank correlations between
continuous variables were calculated. For comparisons of mean levels of contin-
uous variables, 2-sample t-tests were used for unpaired data and paired t-tests
for paired data. Univariate hazard ratios (for changes approximating 1 SD for
each variable) were calculated from Cox proportional hazards models (20) re-
lating rheological variables to three major study endpoints (definite non-fatal
MI or CHD death: the primary study endpoint; CHD death; and all-cause mor-
tality). Corresponding multivariate hazard ratios for selected rheological varia-
bles were calculated after adjusting for a hierarchy of baseline covariates rele-
vant to CHD risk: (1) age and treatment group (pravastatin/placebo); (2) + cur-
rent tobacco-smoking (yes/no); (3) + lipids (HDL, LDL and VLDL cholesterol;
log triglyceride); (4) + other risk factor covariates: height, weight, body mass
index, systolic and diastolic blood pressures, alcohol (units/week), diabetes
(yes/no), hypertension (yes/no), school leaving certificate or better (yes/no),
widowhood (yes/no) and current employment (yes/no); (5) + CHD indicators:
nitrate use (yes/no), minor ECG abnormality (any of Minnesota Codes 4–2,
4–3, 5–2, 5–3: yes/no), positive Rose angina or intermittent claudication
questionnaire (yes/no), or family history of premature CHD (yes/no). All 
p-values from the Cox models are for the Wald statistic.
Results
Table 1 shows the baseline distributions of rheological variables as
well as their relationships to smoking habit. All rheological variables
were related to smoking habit (overall F tests, P <0.0001). Plasma vis-
cosity, fibrinogen, mean red cell volume, white cell count and platelet
count were all significantly higher in current smokers than in former
smokers, who in turn had significantly higher levels than in men who
had never smoked. Blood viscosity, haematocrit and red cell count 
were significantly higher in current smokers than ex-smokers, whose
levels were not significantly different from men who had never smoked,
apart from having a lower red cell count. Significant correlations were
observed between fibrinogen and plasma viscosity (Spearman r = 0.47),
white cell count (r = 0.33) and blood viscosity (r = 0.30); plasma visco-
sity and white cell count (0.26) and haematocrit (r = 0.21); haematocrit
and white cell count (r = 0.26); mean red cell volume and red cell count
(r = –0.40); and white cell count and platelet count (r = 0.22).
Table 2 summarises the relationships of rheological variables to con-
tinuous risk factors. Plasma and blood viscosity were positively related
to triglyceride, cholesterol, VLDL and LDL levels; and inversely rela-
ted to HDL cholesterol levels. Plasma and blood viscosity were also 
positively related to systolic and diastolic blood pressure. Fibrinogen,
haematocrit and white cell count showed similar, but weaker, relation-
ships to these risk factors, with the exception of HDL which was inver-
sely related to fibrinogen and white cell count, and positively related to
mean cell volume. Plasma viscosity and fibrinogen increased with age,
while haematocrit and red cell count decreased slightly with age.
Height was inversely associated with plasma viscosity, fibrinogen, 
Table 1 Distributions of rheological variables and relationships to smoking
habit. Data are given as mean (SD)
Table 2 Relationships of rheological varia-
bles to risk factors which are continuous 
variables. Data are given as Spearman rank
correlation coefficients, where p < 0.05. The
abbreviations for rheological variables are 
given in Table 1
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Table 3 Relationships of rheological varia-
bles to risk factors which are categorical 
variables, and to baseline evidence of cardio-
vascular disease. Data are given as percentage
of one SD increase in each rheological varia-
ble in the presence (relative to the absence) of
each categorical variable, where p < 0.05, 
* p < 0.01, ** p < 0.001, *** p < 0.0001. The
coefficient of variation of each rheological 
variable in the study population is also given.
See text for interpretation
Table 4 Baseline levels [mean (SD)] of
rheological variables by the three major outco-
mes of the WOSCOPS Study; and univariate
hazard ratios (95% CI) and probability values
for the 3 major outcomes for event versus no
event for approximate 1 SD increase in base-
line level of variable
Table 5 Multivariate hazard ratios (95%
CI) and p-values for three major outcomes
by baseline levels of fibrinogen, plasma vis-
cosity, blood viscosity, haematocrit, and
white cell count, adjusted for a hierarchy of
baseline covariates. (Firstly for age and 
treatment group; subsequently for smoking;
lipids (HDL, LDL and VLDL cholesterol;
log triglyceride); other risk factors; and
CHD indicators; as defined in the methods
section)
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white cell count and platelet count; while weight and body mass index
were positively related to red cell count and inversely related to mean
cell volume.
Table 3 summarises the relationships of rheological variables to risk
factors which are categorical variables (not employed, alcohol con-
sumption greater than 20 units per week, history of diabetes or hyper-
tension), as well as baseline evidence of cardiovascular disease (nitrate
consumption, abnormal ECG, history of angina or claudication on 
Rose questionnaire). Data are expressed as the percentage of one stan-
dard deviation increase in each rheological variable in the presence of
each categorical variable, where this increase is statistically significant
at p < 0.05. The standard deviation of each rheological variable is 
given in the first column of Table 1. For example, the mean increase in
plasma fibrinogen in unemployed men compared to those in employ-
ment is 29% of one standard deviation, = 0.29  0.86 g/L, = 0.25 g/L.
Expression of the data in this way allows comparison of the associations
of categorical risk factors or measures of cardiovascular disease with
rheological variables, whose coefficients of variations in the study 
population (also given in Table 3) differ widely, e.g. from 4.5% for
MCV to 27.9% for white cell count. The only significant correlation of
the platelet count (coefficient of variation 22.9%) was a higher level in
men with claudication compared to men without claudication (294 ± 67
vs. 284 ± 109/L; p = 0.039; 15% SD increase). 
Table 4 shows that mean baseline levels of all rheological variables
(except platelet count) were significantly higher in men who sub-
sequently experienced the primary endpoint (non-fatal myocardial 
infarction or definite CHD death) compared to men who did not. This
table also shows mean baseline levels in men who died from CHD 
(definite and suspect) and from all causes; and gives hazard ratios for
these outcomes which were associated with approximately one stand-
ard deviation increase in each rheological variable on univariate ana-
lyses. The hazard ratios of the primary endpoint associated with increa-
ses in plasma viscosity of 0.1mPa.s, in fibrinogen of 1g/L, and in 
white cell count of 2  109/L were each strong (1.31–1.33). The hazard
ratio of the primary endpoint associated with increased blood viscosity
was 1.25, and for haematocrit was 1.22, which in turn reflected the ap-
parently equal increases in the hazard ratios of its two determinants:
mean red cell volume and red cell count (both 1.12). The hazard ratios
for CHD death and for all-cause death associated with rheological 
variables were generally similar to those for the primary endpoint, 
except that fibrinogen appeared a stronger predictor of both CHD death
and total mortality (risk ratios 1.50 and 1.44 respectively) than of the
primary endpoint. 
Table 5 shows the effects of progressive adjustments in multiva-
riate analyses for treatment group and age; CHD risk factors; and 
evidence of baseline CHD on the associations (hazard ratios) of base-
line rheological variables with outcomes. Plasma and blood viscosity,
haematocrit and white cell count remained significantly associated 
with the primary endpoint after all these adjustments: the most signifi-
cant of these residual associations being blood viscosity [hazard ratio
1.14 (1.05, 1.23); p = 0.0025]. The association of fibrinogen was 
reduced to borderline statistical significance (p = 0.073) after inclusion
of multiple CHD indicators in the model; as was its association with
CHD death. The associations of rheological variables with all-cause
mortality became non-significant after inclusion of smoking: with 
the exception of fibrinogen which remained a significant association of
all-cause mortality after all adjustments [hazard ratio 1.18 (1.02, 1.36);
p = 0.022].
Table 6 shows baseline and 1-year levels of lipoproteins and rheo-
logical factors by treatment group. There were no significant differences
between treatment groups at baseline. Plasma viscosity fell by about
one quarter of a standard deviation in the pravastatin group (mean change
–0.19 mPa.s, 95% CI –0.022, –0.016) and the mean plasma viscosity
change over baseline at 1 year was significant (p < 0.0001). Calculated
blood viscosity also fell by about one quarter of a standard deviation 
in the pravastatin group (mean change –0.062 mPa.s, 95% CI –0.072,
–0.052) and again the between group change over baseline at 1 year was
significant (p < 0.0001). No significant effect of pravastatin on fibrino-
gen, haematocrit or white cell count was observed (Table 6). The fall in
plasma viscosity appeared to be related more to the 25% reduction in
Table 6 Baseline and 1-year levels of lipo-
proteins and rheological variables by treat-
ment group. Data are given as mean (SD)
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LDL than to the 10% reduction in VLDL; changes over baseline for
plasma viscosity in both treatment groups were related significantly to
changes in LDL (Spearman r = 0.19) but only marginally to changes in
VLDL (r = 0.08). While changes in plasma viscosity were more strong-
ly related to changes in fibrinogen (r = 0.30), the reduction in plasma
viscosity in the pravastatin group was not attributable to reduction in 
fibrinogen.
Discussion
In this large study of hypercholesterolaemic men, we have first 
confirmed that rheological variables are associated with several major
cardiovascular risk factors, as previously shown in some epidemiolo-
gical and case-control studies (5, 7–11, 21). These include correlations
of baseline plasma and blood viscosity with cholesterol, triglyceride,
LDL and VLDL (r = 0.10–0.24). Second, we observed correlations of
rheological variables with prevalent cardiovascular disease, which
again are consistent with previous reports (5, 8, 9, 21). 
Third, we confirmed the findings of four prospective epidemiologi-
cal studies that plasma viscosity (10, 12, 13, 14, 23) and whole blood
viscosity in one study (13) are associated with incident CHD events. As
in these epidemiological studies, the predictive value of plasma visco-
sity was due partly to plasma fibrinogen, which correlated with plasma
viscosity (Spearman r = 0.47) and which was also a predictor of CHD
events, as in prospective epidemiological studies (22). The association
of haematocrit with incident CHD events also confirms epidemiologi-
cal studies (23) and appeared in the present study to reflect approxima-
tely equal contributions from its two determinants: mean red cell vol-
ume and red cell count (Table 4). The strength of these associations of
rheological variables with incident CHD was similar to that of major
CHD risk factors in the present study (2). For example, the hazard rat-
ios of the primary endpoint associated with 1SD increases in plasma vis-
cosity, fibrinogen or white cell count (1.31–1.33) were similar to the
hazard ratios for an increase of 5 years in age (1.35) or a 20 mmHg in-
crease in systolic blood pressure (1.29) previously reported in this stu-
dy (2). On multivariate analyses of rheological variables including tre-
atment group, CHD risk factors and evidence of baseline CHD, blood
viscosity showed independent associations with CHD risk (Table 5).
This finding suggests that increased blood viscosity may promote
CHD, independently of the potentially confounding effects of CHD risk
factors and of detectable baseline CHD. The associations of fibrinogen
and white cell count with incident CHD may, of course, reflect a possi-
ble role of inflammatory markers in CHD (22), as well as their rheol-
ogical effects (23). The independent association of fibrinogen with 
total mortality in this study was also observed in the Scottish Heart
Health Study (24).
Finally, we have shown that pravastatin treatment lowered plasma
and blood viscosity significantly after 1 year. This was partly attributa-
ble to reduction in plasma LDL (which fell by 25% on pravastatin 
treatment) and partly to reduction in VLDL (which fell by 10%). These
findings are consistent with the report of a small, short-term study of
pravastatin (25) and with clinical and epidemiological studies relating
LDL, VLDL or total cholesterol to plasma or blood viscosity (5, 7–12).
It is possible that part of pravastatin’s effect on viscosity results from a
non-lipid mechanism of action (26). The reduction in plasma viscosity
during pravastatin therapy was not related to change in plasma fibrino-
gen, which increased slightly in both pravastatin and control groups,
possibly simply due to ageing (5). While smoking affects fibrinogen
and viscosity (Table 1), there was no significant change in smoking 
habit between treatment groups (data not shown). While a previous
small study reported a reduction in plasma fibrinogen during pravasta-
tin therapy (25), other, larger studies of pravastatin have generally not
shown any change in fibrinogen (27, 28). 
Whether or not the results of the current study are specific for prava-
statin, or apply to other interventions which lower plasma lipoproteins,
is not established. Variable effects of other statins, fibrates and other
lipid-lowering interventions on viscosity and fibrinogen have been 
reported, in studies which are much smaller, and of shorter duration,
than the present study (5, 27, 28). The net effects of these other drugs
on viscosity will presumably depend on their various effects on diffe-
rent lipoproteins, fibrinogen, and other plasma proteins with rheo-
logical effects (5, 27, 28). Further large, randomised trials are required
to establish the rheological effects of other lipid-lowering agents. 
While the magnitude of the reductions in plasma and blood visco-
sity by pravastatin may appear small (due to the SI units used), they 
correspond to approximately one quarter of a standard deviation for the
study population, and also correspond to the mean differences between
men who experienced the primary outcome and men who did not 
(Table 4). The plasma viscosity reduction on pravastatin treatment is 
also consistent with decreases in risk ratios for study outcomes of 6–8%
(Table 4), and with similar decreases in CHD risk in other prospective
studies of plasma viscosity (23). It is therefore plausible that viscosity
reduction may account for about one-quarter of the CHD risk reduction
by pravastatin; while the remaining risk reduction may reflect other 
mechanisms including effects on coronary artery plaques, endothelial
function and thrombotic tendency (3, 4, 6, 28). We suggest that the 
early (1 year) reduction in viscosity on pravastatin treatment may be
one plausible mechanism for the early (1 year) reduction in CHD events
in WOSCOPS (1) and possibly in other statin studies (6). However, this
hypothesis remains to be proven, because at present there are no large
interventional studies showing that viscosity reduction lowers the risk
of cardiovascular events (23). Because the reduction in LDL choleste-
rol in the pravastatin group of the present study was established after
one year and was stable for the subsequent four years (1) it is possible
that the reduction in viscosity at one year was maintained throughout
the five years of the study. However, further long-term studies of 
pravastatin and viscosity are required to confirm this, and are currently
in progress. 
Increases in plasma viscosity in the general population increase the
risk of prevalent, symptomatic peripheral ischaemia (claudication) in
the presence of a given degree of atherosclerotic arterial narrowing:
conversely viscosity reduction (e.g. by exercise) reduces ischaemic risk
(21). Viscosity reduction by chronic urokinase therapy also reduces
myocardial ischaemia in the presence of coronary artery disease (29). It
therefore seems biologically plausible to suggest that LDL and VLDL
reduction by pravastatin may partly reduce the risk of CHD events
through reduction in plasma and blood viscosity. In the longer term,
blood viscosity reduction by pravastatin might also reduce atherogene-
sis: we have recently shown that viscosity was an independent pre-
dictor of carotid arterial disease in a prospective study (30). Further 
viscosity reduction might be achieved by reducing plasma fibrinogen, a
major risk predictor for CHD (22), which was an independent predictor
of mortality in the present study. Plasma fibrinogen can be reduced by
cessation of smoking, regular exercise, by certain fibrate drugs, or by
ticlopidine (5, 31). We suggest that measurement of plasma viscosity
and fibrinogen in future trials of lipoprotein reduction may help to 
elucidate the mechanisms for reduction in CHD risk. However, whether
or not viscosity reduction lowers CHD risk remains to be proven in 
future trials. 
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